A Clinical Trial of PD-L1 Inhibitor Durvalumab and PARP Inhibitor Olaparib for Patients With EGFR-Mutated Transformed SCLC
Nobuyuki Takahashi, MD, PhD+more
Discovery of targetable genomic alterations, including mutations of EGFR, have resulted in improved survival for patients with non-small cell lung cancer (NSCLC).1 Although many patients experience robust responses to EGFR-targeted […] Read more
Mitigating Pain in Thoracic Surgery
Bryan V. Anderson, MCHS, PA-C+more
A middle-aged woman walks into the clinic using her right hand to hold her shirt away from her chest. “Even just my shirt brushing against my skin hurts,” she says […] Read more
The Dandelion Dilemma of Brain Metastases: Treating the Whole Lawn or the Weeds Separately
Hina Saeed, MD+more
Approximately, 40% to 60% of patients with small cell lung cancer (SCLC) develop brain metastases (BMs),1 ,2 ,3 and fewer than 15% survive beyond 2 years.4 ,5 Whereas upfront stereotactic […] Read more
New IASLC Grading System for Pulmonary Adenocarcinoma Proposed
Andre L. Moreira, MD, PhD+more
Tumor grading is an important component of a pathology report, as it has been traditionally used as a prognostic indicator. For many tumors, grading is also used to help with […] Read more
Brendon Stiles, MD
Formerly an associate professor of cardiothoracic surgery at Weill Cornell Medicine, Brendon Stiles, MD, is now Chief of Thoracic Surgery and Surgical Oncology and Associate Director of Surgical Services for […] Read more
PET vs. CT in Lung Cancer Surveillance: The ‘Pro’ Side from the Nuclear Medicine Perspective
Asha Kandathil, MDA significant proportion of patients with stage I to III NSCLC or SCLC will have locoregional or distant metastases following curative-intent therapy. Studies have reported local recurrence rates of 22% […] Read more
Patient Perspectives on CT and PET Scans: Imaging Technology Provides Different Benefits, Drawbacks for Each Individual Patient
Ivy Elkins, MBA+more
For patients with metastatic lung cancer, frequent scans are a stark reality of living with cancer. Although most scans happen every 3 months, some clinical trials require scans more often […] Read more
Identification of driver oncogenes in NSCLC is leading the method for accurate patient selection and proper targeting of actionable alterations. Several molecular events have been described, and different biomarkers are […] Read more
Large LDCT Lung Cancer Screening Program Suggests Screening Benefits Far Outweigh the Risks
Elliot Servais, MD, FACSLung cancer screening saves lives. This once controversial statement has now been validated in recent large, randomized trials of low-dose computed tomographic (LDCT) lung cancer screening (LCS) including the National […] Read more
FDG PET–CT Versus CT for Lung Cancer Surveillance: The "Con" Side
Palmi Shah, MDLung cancer remains the leading cause of cancer-related deaths.1 Advances in early detection of lung cancer following the implementation of screening programs and the availability of newer therapies have increased […] Read more